Aptima HPV 16 18/45 Genotype Assay
Gen-Probe Incorporated · Decision date Feb 3, 2026
What did the FDA approve?
FDA records P120007/S034 as a supplement to PMA P120007, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Feb 3, 2026.
FDA approval order statement
Approval for the Aptima HPV 16 18/45 Genotype Assay for expanding the indications to include primary screening.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Microbiology
- Decision date
- Feb 3, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P120007/S034
- Regulatory pathway
- PMA supplement
- Applicant
- Gen-Probe Incorporated
- Product code
- OYB
- Decision code
- APPR
- Decision date
- Feb 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Kit, rna detection, human papillomavirus.
- Applicant
- Gen-Probe Incorporated
- Product code
- OYB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P120007/S034 received
Application receipt date recorded by FDA.
P120007/S033 · Related supplement
Aptima HPV 16 18/45 Genotype Assay (Box 1); Aptima HPV 16 18/45 Genotype Assay (Box 2); Aptima HPV 16 18/45 Genotype Ass
P120007/S034 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P120007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Gen-Probe Incorporated | PMA supplement | Oct 7, 2025 | FDA |
Explore the linked device profile
Other records with product code OYB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
APTIMA HPV ASSAYP100042/S038 | Gen-Probe Incorporated | PMA supplement | Feb 3, 2026 | FDA |
| Gen-Probe Incorporated | PMA supplement | Oct 7, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Gen-Probe Incorporated
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 10210 Genetic Center Dr., San Diego, CA, 92121
Sources and methodology
- Original FDA record: P120007/S034
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
